Travere Therapeutics (TVTX) said late Thursday it priced an underwritten public offering of about 7.8 million shares of its common stock at $16 each for expected gross proceeds of $125 million.
The company granted the underwriters a 30-day option to buy up to an additional about 1.2 million shares. The offering is expected to close on Nov. 12.
Price: 17.25, Change: -0.41, Percent Change: -2.32
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。